정신분열병에서 Quetiapine의 임상적 효과와 안전성

Abstract

Atypical anti psychotics have an improved tolerability profile. and are less likely to cause debilitating extrapyramidal symptoms (EPS) than are the conventional antipsychotics. Quetiapine, the fourth atypical antipsychotic, was marketed in Korea as well as in the United States and is also available in over 70 countries worldwide. Quetiapine has been shown to be effective and well tolerated in patients particularly vulnerable to EPS related to conventional anti psychotics. In this article, we review the clinical trials examining the efficacy. safety. and tolerability of quetiapine in treating patients with schizophrenia.